Assessment of Wall Thickness in Hypertrophic Cardiomyopathy
1 other identifier
observational
110
1 country
1
Brief Summary
Assessment of wall thickness in hypertrophic cardiomyopathy (HCM) is of diagnostic and prognostic importance given its known association with sudden cardiac death. However, data regarding comparison of imaging modalities for this key measurement is lacking. This study seeks to compare assessment of maximum wall thickness between clinically indicated echocardiography (with and without contrast) and clinically indicated cardiac magnetic resonance imaging.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Oct 2014
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
September 5, 2014
CompletedFirst Posted
Study publicly available on registry
September 9, 2014
CompletedStudy Start
First participant enrolled
October 1, 2014
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 25, 2017
CompletedStudy Completion
Last participant's last visit for all outcomes
July 25, 2017
CompletedFebruary 5, 2019
February 1, 2019
2.8 years
September 5, 2014
February 4, 2019
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Left Ventricular Wall Thickness
All subjects will undergo noncontrast echocardiography, contrast echocardiography and cardiac MRI.
approximately 1 week after enrollment
Study Arms (1)
Subjects with HCM
All subjects will undergo noncontrast echocardiography, contrast echocardiography and cardiac MRI.
Interventions
Eligibility Criteria
Adult patients with hypertrophic cardiomyopathy (HCM)
You may qualify if:
- Clinically and echocardiographically defined hypertrophic cardiomyopathy.
- Clinically indicated transthoracic echocardiography as part of the medical evaluation.
- No contradiction to administration of ultrasonic echocardiography contrast.
- Planned clinically indicated cardiac magnetic resonance imaging as part of medical evaluation.
- No contraindication to cardiac magnetic resonance imaging (such as cochlear implants, central nervous system aneurysm clips and other implanted medical devices).
- Age 18 years and older
You may not qualify if:
- \) Insufficient image quality for determination of maximal wall thickness.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Mayo Cliniclead
- GE Healthcarecollaborator
Study Sites (1)
Mayo Clinic in Rochester
Rochester, Minnesota, 55905, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Patricia Pellikka, MD
Mayo Clinic
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor of Medicine, College of Medicine
Study Record Dates
First Submitted
September 5, 2014
First Posted
September 9, 2014
Study Start
October 1, 2014
Primary Completion
July 25, 2017
Study Completion
July 25, 2017
Last Updated
February 5, 2019
Record last verified: 2019-02